Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings

NexgenRx Announces 2025 Year End Results with Continued Increasing Net Income, EBITDA And Revenue Growth

Steady Growth Masks High Payout Ratio and Micro-Cap Liquidity Risks

By The Northwire Desk — AI Analysis Mar 31, 2026 · 18:10 NXG · 0.33 NexgenRx Inc.
Executive Summary
  • NexgenRx released its full-year 2025 financial results on March 31, 2026, reporting revenue of $14.93M, an 8.84% year-over-year increase.
  • EBITDA reached $3.35M, up $1.01M from 2024, while net income climbed to $1.29M, representing a 59% YoY increase.
  • The company ended the fiscal year with $4.78M in cash after distributing $1.30M in dividends to common and preferred shareholders.
  • Management highlighted a 12% combined increase in administration and transaction revenue, emphasizing recurring revenue stability and a healthy sales pipeline for 2026.
  • This follows the Q3 2025 release (November 2025), which showed stronger quarterly momentum with 13.43% revenue growth and $0.89M EBITDA, and a December 2025 dividend declaration of $0.005 per share.
Material Impact
  • The FY2025 results confirm a steady, predictable growth trajectory but do not introduce unexpected catalysts or operational shifts.
  • The full-year revenue growth of 8.84% trails the Q3 quarterly growth rate of 13.43%, indicating Q4 2025 growth decelerated.
  • Cash improved from $2.54M at the end of Q3 to $4.78M at year-end, driven by seasonal collections and operational cash flow.
  • The dividend payout of $1.30M nearly matches the full-year net income of $1.29M, leaving virtually zero retained earnings for reinvestment. This high payout ratio is a structural constraint for a company claiming to fund new product launches and pipeline expansion.
  • Market reaction has been muted. The stock peaked at $0.43 in November 2025 following the Q3 beat and has since drifted into the $0.31-$0.36 range, suggesting the positive results were already priced in and investors are cautious about the payout-to-earnings dynamic.
NXG · Price
Company Overview
  • NexgenRx operates in the healthcare technology and pharmacy services sector, generating revenue through administration, transaction processing, and recurring software/service models.
  • The flagship offering centers on pharmacy management and administrative platforms that streamline transaction workflows for healthcare providers.
  • The business model relies heavily on recurring revenue streams and a sales pipeline focused on expanding market presence and deploying new product solutions in 2026.
  • No specific flagship project name or detailed product roadmap was disclosed in the provided releases.
Read the original news release →

More from NexgenRx Inc.

May 21, 2026 · 20:15

NexgenRx Sustains Growth Trajectory with Q1 Profitability; AI Initiative Signals Digital Push

Earnings Nov 20, 2025 · 19:55

NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth

Earnings